 |
 |
||||||||||||||
|
|
| OMML Neuroscience |
| We perform non-clinical experiments to discover and develop novel central nervous system therapeutic treatments for neuropsychiatric diseases including schizophrenia and depression. |
| * OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.
0109W-0602 |